The South Korean Ministry of Health and Welfare announced on October 15, 2026 that it had newly selected seven inherited conditions for its list of conditions eligible for embryo or fetal genetic testing. The list now contains 264 conditions in total, including those seven. Another four specific conditions are still being reviewed. These figures answer different questions. Neither the announcement nor a name match decides whether testing is medically indicated, available to a particular family or covered by insurance.
Which list answers which question?
| Question | Part of the official Korean PDF | What it does not establish |
|---|---|---|
| Which seven were just added? | Attachment 1 (붙임 1) | Not the entire list |
| What is on the current announced list? | Attachment 2 (붙임 2), 264 conditions | Not an individual test authorization |
| Which requests have no final selection announced? | Main release, four conditions under additional review | Not seven newly selected conditions |
The new entries, using the English terms printed alongside the Korean names in Attachment 1, are homocystinuria-megaloblastic anemia, cbl E type; cartilage-hair hypoplasia; TOR1A-related dystonia; SGCE-related dystonia; DPAGT1-related congenital myasthenic syndrome; Pierson syndrome; and palmoplantar keratoderma, epidermolytic, 1. The ministry says the full list is also posted under its website's notices. For a particular family, compare the exact Korean and English disease names, the causative gene and the clinical genetic report with a qualified clinician; similar-sounding conditions need not be the same diagnosis. “Pierson syndrome” here is the term in the source, not an invitation to substitute another similarly named syndrome.
Four pending reviews must not be counted as new approvals
The release separately identifies SDHB-related hereditary tumor predisposition syndrome, MYH7-related cardiomyopathy, FLNC-related cardiomyopathy, and ACTN2-related cardiac and skeletal myopathy as requiring further review. Do not add them to the seven new entries on the strength of this announcement. An older or differently defined cardiomyopathy entry elsewhere in the 264-item list does not settle the status of these four requests.
Experts consider age at onset, lethality and severity, and treatment and management possibilities. The ministry says this committee review addressed requests received by July 15, 2026; that retrospective cutoff is not a newly announced public application deadline. The announcement gives no individualized promise of a result or turnaround time.
A practical, bounded next step
- Open the original release and PDF and identify the exact named condition in Attachment 1 or 2. Do not diagnose from a web search.
- Discuss the family's report, causal variant and clinical history with an obstetric or relevant medical-genetics specialist. A listed condition does not guarantee test availability, eligibility, effectiveness, payment or coverage for any one person.
- If seeking a review of a disease for possible future inclusion, the ministry directs requests through the official e-People petition portal. This is not the same as scheduling a test for an individual. The PDF states that a request may be made only when a genetic variant causing that disease has been identified in the patient. In that case, check the required Korean/English disease name, causative gene, genetic test report confirming the patient's variant, applicant's relationship to the patient, symptoms and age of onset, and a reason for requesting review (such as PGT-M, prenatal testing or future family planning). Check the genuine portal and consult a clinician before submitting sensitive genetic information.
The document describes possible disease-list review, not an individual's medical assessment or an insurance benefits determination. Recheck current official notices if acting later than this announcement.
Korean Naver edition: Embryo and fetal genetic-testing disease list: seven additions and where to check.
About the Author
Life Mokcha separates a government disease-list announcement from individualized clinical decisions.
